Stocktoria
Lantern Pharma Inc. LTRN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-06-11
Lantern Pharma Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $11.5M | $16.1M | $11.9M | $8.6M | $7.6M |
| Operating income | -$18.0M | -$22.2M | -$17.9M | -$14.4M | -$12.6M |
| Net income | -$17.1M | -$20.8M | -$16.0M | -$14.3M | -$12.4M |
| EPS (diluted) | $-1.57 | $-1.93 | $-1.47 | $-1.31 | — |
| Operating cash flow | -$15.7M | -$17.8M | -$14.3M | -$12.8M | -$10.6M |
| Free cash flow | -$15.7M | -$17.8M | -$14.4M | -$12.8M | -$10.6M |
| Cash & equivalents | $4.4M | $7.5M | $21.9M | $37.2M | $51.5M |
| Total assets | $11.0M | $25.6M | $43.6M | $58.8M | $74.0M |
| Total liabilities | $4.5M | $4.4M | $2.7M | $2.8M | $2.4M |
| Shareholders' equity | $6.5M | $21.2M | $40.9M | $56.0M | $71.6M |
Source: SEC EDGAR filings · CIK 0001763950 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.